VALCHLOR mechlorethamine

Drug Class

Topical alkylating agent

Mechanism

Alkylates DNA and cross-links DNA strands to inhibit DNA replication and induce apoptosis in neoplastic T-cells.

Approved Indication

Topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy.

What This Means For Patients

VALCHLOR is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2013) — Sources
• EMA — Approved (2020) — Sources

Pivotal Clinical Evidence

• Study 201 — Lessin et al., JAMA Dermatol 2013 (NCT00168064) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202714s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/ledaga